Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes.

Abstract

Daiichi Sankyo Inc is developing rivoglitazone, an insulin sensitizer with peroxisome proliferator-activated receptor gamma agonistic activity, for the potential treatment of type 2 diabetes. By March 2006, phase I/III clinical trials were underway in the US and the EU.